AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
First quarter 2002 performance: net loss of $0.29 per share.(GenVec Inc.)(Brief Article)(Statistical Data Included)
2002 JUN 12 - (NewsRx.com & NewsRx.net) -- GenVec, Inc., (GNVC), a biopharmaceutical company developing gene-based medicines, announced financial results for the first quarter ended March 31, 2002. GenVec reported a net loss of $6.4 million or ($0.29) per share compared with a net loss of $3.3 million or ($0.18) per share in the comparable quarter of 2001. GenVec ended the first quarter of 2002 with $34.4 million in cash and investments.
Revenues for the quarter ended March 31, 2002 were $628,000 compared with $2.0 million for the same period last year. Revenue for the current quarter was primarily attributable to the commencement of activities under the company's new $10.2 million collaboration with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) under which GenVec will use its proprietary adenovector technology for the development and manufacture of clinical grade preventative AIDS vaccine candidates.
The overall decline in revenue was due to the absence of payments under the company's research and development agreement with Pfizer, Inc. Under the terms of the 1997 agreement, Pfizer will be responsible for all development costs associated with the phase II clinical trials of BioBypass through July 22, 2002, including the costs related to the orderly transfer to GenVec of the investigational new drug (IND) applications for both the coronary artery disease and ...
- GenVec to Present Final Data From Phase Ib Clinical Trial of TNFerade In...
- Press release article from: PR Newswire November 8, 2002 700+ words
...Meeting in San Diego, CA GenVec, Inc. , a biopharmaceutical...final results from its Phase Ib clinical trial of lead...3:30 p.m. PT). GenVec will also issue a press...the findings from the Phase Ib study of TNFerade in...variety of solid tumors. GenVec will re-issue the ...
- GenVec Completes Patient Accrual in Phase Ib Dose Escalation Trial of TNFerade...
- Press release article from: PR Newswire April 10, 2002 700+ words
...PRNewswire-FirstCall/ -- GenVec, Inc. , a biopharmaceutical...completed patient accrual in its Phase Ib dose escalation trial for TNFerade...Florida. Dr. Paul H. Fischer, GenVec's President and Chief Executive...commented, "With TNFerade, GenVec is combining gene therapy and...
- GenVec and Varian Medical Systems Extend Collaborative Agreement Through 2004.
- Press release article from: PR Newswire June 20, 2001 700+ words
Phase Ib Clinical Trial Combining...PRNewswire/ -- GenVec, Inc. (Nasdaq...treatment of cancer. A Phase Ib clinical trial of...were achieved. "GenVec is pleased to continue...cancer patients." GenVec has commenced a Phase Ib clinical trial with...
- GenVec Expands Clinical Development of TNFerade in Cancer.
- Press release article from: PR Newswire October 1, 2001 700+ words
...M.D., Ph.D., GenVec's Vice President of...Earlier this year, GenVec announced the initiation of Phase Ib studies of TNFerade in...development program." GenVec also announced that interim Phase Ib clinical trial data from...
- GenVec Expands Clinical Testing of AdPEDF for Macular Degeneration.
- Press release article from: PR Newswire February 22, 2005 700+ words
GenVec, Inc. today announced that...Hopkins School of Medicine. The Phase IB study will compare two doses...Lisa L. Wei, Ph.D., GenVec's director of preclinical...abnormal blood vessel growth." GenVec is a biopharmaceutical company...
- GenVec Announces Third Quarter 2001 Financial Results.
- Press release article from: PR Newswire October 25, 2001 700+ words
...agreement still in place, GenVec has the potential to receive...Pfizer. TNFerade(TM), GenVec's lead oncology product candidate, is now in two Phase Ib trials in combination with...variety of solid tumors. GenVec will present the first clinical...
- GenVec Announces Second Quarter 2001 Financial Results and Mid-Year Update.
- Press release article from: PR Newswire August 1, 2001 700+ words
...disease. Dr. Paul H. Fischer, GenVec's President and Chief Executive Officer commented, "GenVec is focused on moving its portfolio...is being evaluated in two Phase Ib clinical trials for use in...important to recognize that GenVec's internal product development...
- GenVec Reports Fourth Quarter and Fiscal Year End 2001 Financial Results.
- Press release article from: PR Newswire February 28, 2002 700+ words
...private placement transaction. GenVec ended the year 2001 with...2002, Jeffrey W. Church, GenVec's chief financial officer...esophageal cancer * Initiate a Phase Ib trial using AdPEDF for the...support of those trials." GenVec is a publicly held biotechnology...
- Morning Alert for GenVec Inc.
- Press release article from: M2 Presswire April 2, 2007 700+ words
...GenVec Inc (NASDAQ:GNVC) GenVec, Inc., a biopharmaceutical...TNF-alpha in the tumor. GenVec is developing TNFerade Biologic...disease; AdPEDF, which is in Phase IB trial for the treatment of...Pharmaceuticals Industries, Ltd. GenVec was founded in 1992 and is...
- TNFerade gene therapy causes tumor shrinkage at lowest doses.(clinnical trials...
- Newspaper article from: BIOTECH Patent News November 1, 2001 700+ words
GenVec, Inc. (Gaithersburg, MD...candidate, TNFerade. The interim Phase Ib clinical trial results were...directly to tumors, using GenVec's proprietary adenovector...and Regulatory Affairs for GenVec, Inc. Dr. Rasmussen continued...
Source: HighBeam Research, First quarter 2002 performance: net loss of $0.29 per share.(GenVec...